RedNVIA - Seoul, South Korea

Operator of a pharmaceutical company intended to develop new drugs through repositioning. The company focuses on repositioning an already approved and widely used anti-diabetes drug as a medication that slows or stops the progression of calcific aortic valve disease, thus providing the healthcare sector with new technology and medication for a problem that currently has no other remedy.